The PRIMA bionic retina implant is an investigational treatment for advanced dry age-related macular degeneration (geographic atrophy). A wireless, light-sensitive chip about 2 mm square is implanted under the retina; camera glasses project an infrared image onto it, the chip converts that light into electrical signals, and the surviving nerve cells of the retina carry those signals to the brain. In the European PRIMAvera pivotal trial, reported in 2025, treated patients regained the ability to read letters and words they could no longer see. PRIMA is not yet a routine, commercially available operation in the UK — access is currently through clinical trials and specialist centres. Our consultants can assess your macula, explain where the science stands, and start you on the dry AMD treatments available today.
What is the PRIMA bionic retina?
Age-related macular degeneration is the leading cause of sight loss in the UK. In the advanced “dry” form, called geographic atrophy, the light-sensing cells in the centre of the retina (the macula) gradually die, leaving a blank or dark patch in the middle of vision. Until recently there was nothing that could restore that lost central sight — only treatments that slow further loss.
PRIMA takes a different approach. Rather than trying to save dying cells, it replaces the function of the lost photoreceptors with technology. The implanted chip acts as an artificial layer of light-sensitive pixels. Because deeper retinal nerve cells often survive in geographic atrophy, the chip can stimulate them directly, creating a new pathway for visual information to reach the brain. The system was developed by Pixium Vision and Stanford University; the technology has since passed to Science Corporation, which is continuing its development.
Who is PRIMA designed for?
- Advanced dry AMD (geographic atrophy) affecting the centre of both eyes
- Loss of central vision while peripheral (side) vision remains
- People who can no longer read, recognise faces or see fine detail
- Not for wet AMD, and not a treatment for early or intermediate dry AMD
- Suitability is decided by detailed retinal imaging and assessment
Living with central vision loss from dry AMD? A consultant retinal assessment clarifies your diagnosis, your prognosis and every option open to you — today and on the horizon.
Book a retinal assessmentHow PRIMA works — and the dry AMD options available now
PRIMA is part of a fast-moving field. While the implant itself remains investigational, several treatments to slow geographic atrophy and support remaining vision are available to private patients now. Your consultant will explain which apply to you.
It is important to be clear-eyed about what each does. Injections and emerging therapies aim to slow the disease; the PRIMA implant aims to give some sight back. None is a cure, and the implant’s long-term role is still being established. Compare the two main forms of the disease in our guide to wet AMD vs dry AMD treatment options.
How the implant is placed
In the trial setting, implanting PRIMA is a specialised vitreoretinal operation performed by a retinal surgeon, usually under local or general anaesthetic.
- A standard vitrectomy is performed to access the back of the eye.
- A small opening is made and the chip is positioned under the retina at the centre of the macula, then the retina is settled back over it.
- The eye heals over several weeks while the implant integrates with the surrounding tissue.
- The patient is then fitted with camera glasses that capture the scene and project a processed infrared image onto the chip.
- A programme of visual rehabilitation trains the brain to interpret the new signals — this learning phase is central to the result.
Because this is investigational surgery, it is only carried out within approved studies at specialist centres, with careful selection and consent.
Rehabilitation and what to expect
Unlike cataract surgery, the benefit from a retinal implant is not immediate — it builds gradually as the brain learns to use the device. The trial experience gives a realistic picture:
First weeks
The eye heals from surgery. The implant is not yet activated for everyday use; follow-up confirms the chip is correctly positioned.
Activation
Camera glasses are fitted and switched on. Early perceptions are basic — patterns of light — rather than instant clear vision.
Months 1–6
Structured training teaches the brain to interpret signals from the chip. Reading of letters and words develops with practice.
Beyond 6 months
In PRIMAvera, treated patients could read lines on a chart they previously could not see, using the implant together with their remaining side vision.
Ongoing
The implant supplements, rather than fully replaces, natural sight. Long-term durability and wider results continue to be studied.
Availability and cost in the UK
We want to be straightforward: in 2026 the PRIMA bionic retina implant is not a routine private or NHS operation in the UK, and there is no standard self-pay price for it. It is available only through clinical trials and specialist research centres, following regulatory review. Beware any clinic advertising it as a ready-to-book commercial procedure.
- PRIMA implant: investigational — access via approved clinical trials only.
- Consultant retinal assessment: from £250, including OCT macular imaging and an honest discussion of your options.
- Dry AMD treatments available now: see Syfovre and Izervay geographic-atrophy injection pricing.
- Low-vision support: aids and rehabilitation to make the most of remaining sight.
What our consultants can do today is confirm your diagnosis, treat what is treatable, protect your remaining vision, and tell you honestly when a technology like PRIMA becomes a realistic option for you. Read more about dry AMD treatment and macular degeneration.